NeuroVive presents innovative metabolic regulators for NASH. Abstract selected as top tier at The Liver Meeting 2017
Lund, Sweden, 3 October 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that an abstract with new preclinical data related to the company’s project NVP022 for non-alcoholic steatohepatitis (NASH) has been accepted for presentation at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington DC, October 20-24, 2017.NVP022 targets the metabolic components of NASH by using mild, liver-targeted protonophores to increase energy expenditure, remove excess fat